Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Body Radiotherapy (SBRT) Combined With PD-1 Inhibitor and Chemotherapy in Early-stage Treatment-naive Triple-negative Breast Cancer Patients: A Multicenter Phase III Clinical Study

NCT06627712 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT06627712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06627712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Body Radiotherapy (SBRT) Combined With PD-1 Inhibitor and Chemotherapy in Early-stage Treatment-naive Triple-negative Breast Cancer Patients: A Multicenter Phase III Clinical Study
Lead sponsor
West China Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
November 1, 2024
Completion date
November 1, 2031
Enrollment
318 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer